

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,818,216 B2
APPLICATION NO. : 09/996288
DATED : November 16, 2004
INVENTOR(S) : James F. Young et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 37, lines 63-64, change "with the exception that there is an amino acid substitution of an alanine for a valine at position 109." to --with the exception that there is a valine at position 103, numbered as shown in Figure 2A, and a glutamine at position 112, numbered as shown in Figure 2B.--.


Col. 41-42, Table 2, change "***A4B4L1" to --***A4B4L1FR-S28R--.

Col. 94, lines 48-56, change "Fab fragments having the framework sequences of FIG. 1 and the indicated CDR sequences indicated listed in Table 2. SYNAGIS® AND AFFF are actual monoclonal antibodies with the framework sequences of FIG. 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of these antibodies may differ slightly from those of the Fab fragments." to --Fab fragments having the framework sequences of FIG. 2 and the CDR sequences listed in Table 2. SYNAGIS® is a monoclonal antibody with the framework sequences of Figure 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of this antibody may differ slightly from those of the Fab fragments.--.

Col. 123, SEQ ID NO:11 (amino acid 103), line 27, change "Leu" to --Val--.

Signed and Sealed this

Seventh Day of August, 2007



JON W. DUDAS
Director of the United States Patent and Trademark Office